Portfolio
← 실적 발표
01
02
03
04 05 06
톤
자본지출
A1 A2
IFF
FY2025 Q4
개선
International Flavors & Fragrances, Inc. 실적 발표
Buzzberg 분석
Food ingredients sale process officially launched, strong interest from strategics and sponsors.
IFF reported Q4 2025 results in line with expectations, showing modest revenue growth and strong EBITDA expansion. Management's guidance for 2026 is cautiously optimistic, expecting volume-led growth, but acknowledges macro uncertainties and the ongoing food ingredients divestiture. The company is actively reshaping its portfolio toward high-value, innovation-driven businesses (Taste, Scent, Health & Biosciences) while managing down debt and improving cash flow. Portfolio reshaping is a key theme: announced sale process for food ingredients, with strong interest from strategics and financial sponsors; also closing the sale of soy businesses to Bunge and completed divestitures of Pharma Solutions, Nitrocellulose, and Rene Laurent.
Buzzberg 분석 Food ingredients sale process officially launched, strong interest from strategics and sponsors. IFF reported Q4 2025 results in line with expectations, showing modest revenue growth and strong EBITDA expansion. Management's guidance for 2026 is cautiously optimistic, expecting volume-led growth, but acknowledges macro uncertainties and the ongoing food ingredients divestiture. The company is actively reshaping its portfolio toward high-value, innovation-driven businesses (Taste, Scent, Health & Biosciences) while managing down debt and improving cash flow. Portfolio reshaping is a key theme: announced sale process for food ingredients, with strong interest from strategics and financial sponsors; also closing the sale of soy businesses to Bunge and completed divestitures of Pharma Solutions, Nitrocellulose, and Rene Laurent. 전체 분석 보기분석 접기
IFF reported Q4 2025 results in line with expectations, showing modest revenue growth and strong EBITDA expansion. Management's guidance for 2026 is cautiously optimistic, expecting volume-led growth, but acknowledges macro uncertainties and the ongoing food ingredients divestiture. The company is actively reshaping its portfolio toward high-value, innovation-driven businesses (Taste, Scent, Health & Biosciences) while managing down debt and improving cash flow. Portfolio reshaping is a key theme: announced sale process for food ingredients, with strong interest from strategics and financial sponsors; also closing the sale of soy businesses to Bunge and completed divestitures of Pharma Solutions, Nitrocellulose, and Rene Laurent.
- FY2026 guidance is for comparable currency neutral sales growth of 1-4% and EBITDA growth of 3-8%, driven primarily by volume. Management expects pricing to be slightly down, mainly on commodity fragrance ingredients.
- The company is emphasizing cash flow generation and working capital discipline, introducing a new incentive metric for 2026, and expects meaningful cash flow improvement over 2025.
- Innovation is a core driver for future growth, particularly in areas like enzymes, natural ingredients, and biotechnology-enabled solutions like EnviroCaps and Super Carrot.
매출$2.589B보고값
주당순이익(EPS)$0.80보고값
매출총이익률34.38%보고값
영업이익률4.36%보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Guidance
2026 sales guidance of 1-4% growth driven entirely by volume, pricing slightly down.
Demand
Health business expected to flatten in H1 and grow in H2 2026.
핵심 내용 3개 더 보기
Margins
Incremental margins on volume are roughly 30-35%.
Cash Flow
Free cash flow improvement is a key priority for 2026, with new incentive metric.
Portfolio
Fragrance ingredients commodity portfolio under pressure, shifting to specialties.
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $2.589B | 보고값 |
| 주당순이익(EPS) | $0.80 | 보고값 |
| 매출총이익률 | 34.38% | 보고값 |
| 영업이익률 | 4.36% | 보고값 |
| 잉여현금흐름 | $0.13B | 보고값 |
| 자본지출 | $0.188B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 자본지출 | FY2026 | 6% | 6% | 제시 |
| 영업이익률 | FY2026 | $2.05B–$2.15B | $2.1B | 제시 |
| 매출 | FY2026 | $10.5B–$10.8B | $10.65B | 제시 |
AI, 자본지출 및 수요 분석
경영진 분석
Confident
Management expressed conviction in their strategic direction, portfolio optimization, and growth trajectory despite acknowledging macroeconomic challenges.
투자 및 생산능력
CapEx is expected to be around 6% of sales in 2026, carefully managed and focused on highest return opportunities including capacity expansion, network optimization, and innovation to support long-term growth.
아래에 언급된 기업 1개 모두 표시
기업발표 이후 수익률
파트너
파트너
Eric Feerwald
IFF is divesting its soy businesses to Bunge, reflecting continued portfolio reshaping; likely part of broader strategic consolidation in agricultural processing.
근거
“announced an agreement to sell our soy crush, concentrates, and lecithin businesses to Bungee, which we expect to happen by April”
외부 신호
공급망 알파 · 2발표 이후 수익률
IFF expects full year 2026 pricing to be slightly down, primarily due to continued price competition and softness in commodity fragrance ingredients. The company is shifting toward higher-value specialty ingredients to mitigate this.
근거
“We do expect pricing to be slightly down, which is primarily related to the commodity portion of our fragrance ingredients”
IFF has officially launched the sales process for its food ingredients business and has seen interest from strategics and financial sponsors. They expect to capture value, with proceeds used for share buybacks and debt paydown.
근거
“following several months of extensive preparation by our team, we formally launched a disciplined and competitive sale process, and as of two weeks ago, are officially in the market.”
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 1개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.